The rapid advancement of breast cancer screening and prevention technology is cause for excitement and hope in our industry, with AI breast cancer risk assessment quickly moving to the forefront.
The rapid advancement of breast cancer screening and prevention technology is cause for excitement and hope in our industry, with AI breast cancer risk assessment quickly moving to the forefront.
Integrated AI, genetic, and imaging solutions from Clairity, Myriad, and MagView help identify high-risk women and enable earlier breast cancer intervention.
We’re thrilled to announce MagView’s partnership with the Know Your Lemons Foundation—a global leader in innovative …
An exciting technique in mammography, Contrast-Enhanced Mammography (CEM) is an increasingly important and effective method providers …
Fulton, MD – Tuesday, July 22, 2025 – MagView, the leader in mammography tracking and reporting, …
The trend in modern breast healthcare is showing an overwhelming patient preference for digital communication. Patients …
Preparing for an MQSA inspection can be stressful, especially when the stakes are high and the …
In 2019, the FDA announced proposed changes to the mammography facility accreditation requirements that were issued …
Discover how MagView automates mammography notification letters, ensuring MQSA compliance and improving patient communication. Simplify your workflow - schedule your FREE demo today!
